论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Wu J, Long Z, Cai H, Yu S, Liu X
Received 13 December 2018
Accepted for publication 5 April 2019
Published 16 May 2019 Volume 2019:12 Pages 3743—3751
DOI https://doi.org/10.2147/OTT.S198115
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Dr Takuya Aoki
Aim: To study
the carcinogenetic mechanism of HOXB7 in gastric cancer (GC) remains.
Methods: Two human
GC cell lines — SGC7901 and SNU1 — were used for this study. SGC7901 cells were
transfected with siRNA-HOXB7 (siHOXB7) to knock down HOXB7 expression, whereas,
SNU1 cells were transduced with pCDNA3.1-HOXB7 to overexpress HOXB7. After
transfection, cancer progression was assessed by determining cell
proliferation, wound-healing process, cell cycle, apoptosis, invasion, and
migration. The effect of HOXB7 on epithelial–mesenchymal transition (EMT) was measured
by observing changes in F-actin cytoskeleton and evaluating the expression of
EMT markers. p-Scr and p-FAK were evaluated to assess the mechanism.
Results: Knockdown
of HOXB7 suppressed cell proliferation, alleviated the wound-healing process,
inhibited cell migration and invasion, and arrested the cell cycle while
promoting cell apoptosis, suggesting the tumor-suppressive effect of siHOXB7 in
human GC cells. On the contrary, HOXB7 overexpression showed a tumor-promoting
effect on human GC cells. Moreover, we confirmed an inhibitory effect of
siHOXB7 on the EMT process by preventing epithelial cells from acquiring a
mesenchymal phenotype and downregulating mesenchymal markers (vimentin,
β-catenin, N-cadherin, Twist) while upregulating epithelial markers
(E-cadherin). Our data revealed that HOXB7 was associated with Src/FAK and
favored the activation of the Src–FAK pathway in human GC cells.
Conclusion: HOXB7
accelerated the malignancy of GC, by facilitating EMT and regulating the
Scr–FAK pathway.
Keywords: gastric
carcinoma, Homeobox B7, Epithelial-mesenchymal transition, Src, FAK
